Breaking Finance News

Laboratory Corp. Of America Holdings (NYSE:LH) target price raised to $175.00, reported today by Wells Fargo

Boasting a price of $150.31, Laboratory Corp. Of America Holdings (NYSE:LH) traded 0.66% higher on the day. With the last stock price close up 0.98% from the two hundred day average, compared with the S&P 500 Index which has increased 0.03% over the date range. Laboratory Corp. Of America Holdings has recorded a 50-day average of $153.60 and a two hundred day average of $148.80. Volume of trade was up over the average, with 632,529 shares of LH changing hands over the typical 629,666

Laboratory Corp. Of America Holdings (NYSE:LH) had its price target upped to $175.00 by Wells Fargo in a report released Thursday October 12, 2017. The new target price indicates a possible upside of 0.16% based on the company's most recent stock price close.

On 7/13/2017, Credit Suisse Group released a statement for Laboratory Corp. Of America Holdings (NYSE:LH) bumped up the target price from $0.00 to $146.00 that suggested a downside of -0.04%.

Performance Chart

Laboratory Corp. Of America Holdings (NYSE:LH)

With a total market value of $0, Laboratory Corp. Of America Holdings has price-earnings ratio of 21.04 with a one year low of $119.51 and a one year high of $164.22 .

A total of 17 equity analysts have released a ratings update on LH. Four equity analysts rating the company a strong buy, ten equity analysts rating the company a buy, six equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $140.94.

Brief Synopsis About Laboratory Corp. Of America Holdings (NYSE:LH)

Laboratory Corporation of America Holdings is a life sciences company that is integrated in guiding patient care, providing clinical laboratory and end-to-end drug development services. The Company operates as a healthcare diagnostics company. The Company operates through two segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). The LCD segment is an independent clinical laboratory business, which offers menu of frequently requested and specialty testing through an integrated network of primary and specialty laboratories across the United States. The CDD segment offers drug development services, and provides a range of drug research and development (R&D) and market access services to biopharmaceutical companies and medical device companies across the world. It serves a range of customers, including managed care organizations (MCOs), biopharmaceutical companies, governmental agencies, physicians and other healthcare providers.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *